Why the study?
Variants of concern of SARS-CoV-2 and waning immunity cause susceptibility to infection, making identification of correlates of protection necessary to identify susceptible populations.
Does a fourth dose of the BNT162b2 vaccine and specific baseline antibody levels predict the risk of symptomatic SARS-CoV-2 infection in healthcare providers previously vaccinated with three doses?
Cohort (n=608)
Yes
Does a fourth dose of the BNT162b2 vaccine and specific baseline antibody levels predict the risk of symptomatic SARS-CoV-2 infection in healthcare providers previously vaccinated with three doses?
This is the authors' abstract. We don't add key points for this paper.
Variants of concern (VOC) of SARS-CoV2 and waning immunity pose a serious global problem. Overall, vaccination and prior infection provide significant protection, but some individuals remain susceptible to infection and severe disease. Rigorously identifying correlates of protection (COP) is necessary to identify these susceptible populations. We conducted a multicenter prospective study assessing the association between serological profiles and the risk for SARS-CoV-2 infection, comparing those vaccinated with three to four doses of Pfizer BNT162b2 vaccine. We identified several IgG and IgA binding markers that were COPs. The strongest COP was reduced IgG levels to RBD mutants and IgA levels to VOCs (three-dose-group HR=6.34, p=0.008; four-dose-group HR=8.14, p=0.018). Most importantly, we identified a subset of vaccinated individuals with low antibody levels that generated a significant boost in neutralizing antibody titers after a fourth dose, but were still at significantly increased susceptibility to infection.
Baseline IgA and IgG binding antibody levels can identify individuals at increased risk for SARS-CoV-2 infection despite booster vaccination, highlighting novel correlates of protection.
No takes yet. Share an insight, caveat, or question.
Hertz et al. (2022) conducted a cohort in SARS-CoV-2 infection (n=608). Low baseline IgG levels to RBD mutants and IgA levels to VOCs vs. High baseline antibody levels was evaluated on Symptomatic SARS-CoV-2 infection (HR 8.14, p=0.018).
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: